Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab and Radiotherapy in Neoadjuvant NSCLC
NCT06065813Phase 2Recruiting
- Sponsor
- Subei People's Hospital
- Start
- Aug 2022
- Primary completion
- May 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in non-small cell lung cancer (NSCLC), sponsored by Subei People's Hospital. Started Aug 2022; status: recruiting.
02
Drugs
toripalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06065813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06065813.